An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor
Open Access
- 23 March 1998
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 158 (6) , 577-584
- https://doi.org/10.1001/archinte.158.6.577
Abstract
ATORVASTATIN (Lipitor), a highly effective 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitor (statin), suppresses hepatic cholesterol synthesis, thereby promoting an increase in hepatic low-density lipoprotein (LDL) receptors and altering the formation of very-low-density lipoprotein (VLDL) particles.1-3 Dose-dependent reductions in LDL cholesterol levels ranging from 41% to 61% have been reported for the dosage range of 10 to 80 mg/d.4,5 In addition, serum triglyceride levels have been reduced up to 43% in patients with hypertriglyceridemia.6This publication has 19 references indexed in Scilit:
- A brief review paper of the efficacy and safety of atorvastatin in early clinical trialsAtherosclerosis, 1997
- Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-upThe American Journal of Cardiology, 1994
- Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemiaArchives of internal medicine (1960), 1994
- Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality studyEuropean Heart Journal, 1994
- Simvastatin in severe primary hypercholesterolemia: Efficacy, safety, and tolerability in 595 patients over 18 weeksClinical Cardiology, 1993
- Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemiaAtherosclerosis, 1991
- Long-term safety and efficacy profile of simvastatinThe American Journal of Cardiology, 1991
- Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemiaArchives of internal medicine (1960), 1991
- The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemiaJournal of Internal Medicine, 1990
- Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.Proceedings of the National Academy of Sciences, 1986